Are fluoxetine plasma levels related to outcome in obsessive-compulsive disorder?

American Journal of Psychiatry

Volumn 153, Issue 11, 1996, Pages 1450-1454

  Koran, Lorrin M ^a   Cain, John W ^b   Dominguez, Roberto A ^b   Rush, A John ^b   Thiemann, Sue ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; NORFLUOXETINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSESSION; PRIORITY JOURNAL; RATING SCALE; SCORING SYSTEM; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

EID: 0029858120     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.153.11.1450     Document Type: Article

References (26)

1. Depression Guideline Panel: Depression in Primary Care, vol 2: Treatment of Major Depression: AHCPR Publication 93-0551. Rockville, Md, US Department of Health and Human Services Agency for Health Care Policy and Research, 1993
2. Kasvikis Y, Marks IM: Clomipramine in obsessive-compulsive ritualizers treated with exposure therapy: relations between dose, plasma levels, outcome and side effects. Psychopharmacology (Berl) 1988; 95:113-118
3. Stern RS, Marks IM, Mawson D, Luscombe DK: Clomipramine and exposure for compulsive rituals, II: plasma levels, side effects and outcome. Br J Psychiatry 1980; 136:161-166
4. Insel TR, Murphy DL, Cohen RM, Alterman I, Kilts C, Linnoila M: Obsessive-compulsive disorder: a double-blind trial of clomipramine and clorgyline. Arch Gen Psychiatry 1983; 40:605-612
5. Mavissakalian MR, Jones B, Olson S, Perel JM: Clomipramine in obsessive-compulsive disorder: clinical response and plasma levels. J Clin Psychopharmacol 1990; 10:261-268
6. Thoren P, Asberg M, Bertilsson L, Mellstrom B, Sjoqvist F, Traskman L: Clomipramine treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 1980; 37:1289-1294
7. Flament MF, Rapoport JL, Berg CJ, Sceery W, Kilts C, Mellstrom B, Linnoila M: Clomipramine treatment of childhood obsessive-compulsive disorder: a double-blind controlled study. Arch Gen Psychiatry 1985; 42:977-983
8. Greist J, Chouinard G, DuBoff E, Halaris A, Kim SW, Koran L, Liebowitz M, Lydiard RB, Rasmussen S, White K, Sikes C: Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. Arch Gen Psychiatry 1995; 52:289-295
9. Tollefson GD, Rampey AH, Potvin JH, Jenike MA, Rush AJ, Dominguez RA, Koran LM, Shear K, Goodman W, Genduso LA: A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 1994; 51:559-567
10. Yonkers KA, Kando JC, Cole JO, Blumenthal S: Gender differences in pharmacokinetics and pharmacodynamics of psychotropic medication. Am J Psychiatry 1992; 149:587-595
11. Guy W (ed): ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. Washington, DC, US Department of Health, Education, and Welfare, 1976, pp 218-222
12. Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, Heninger GR, Charney DS: The Yale-Brown Obsessive Compulsive Scale, I: development, use, and reliability. Arch Gen Psychiatry 1989; 46:1006-1011
13. Goodman WK, Price LH, Rasmussen SA, Mazure C, Delgado P, Heninger GR, Charney DS: The Yale-Brown Obsessive Compulsive Scale, II: validity. Arch Gen Psychiatry 1989; 46:1012-1016
14. Glantz SA: Primer of Biostatisrics. New York, McGraw-Hill, 1981, pp 87-88
15. Hamilton M: Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967; 6:278-296
16. Beaseley CM, Bosomworth JC, Wernicke JF: Fluoxetine: relationship among dose, response, adverse events, and plasma concentrations in the treatment of depression. Psychopharmacol Bull 1990; 26:18-24
17. Bergstrom RF, Lemberger L, Faid NA, Wolen RL: Clinical pharmacology and pharmacokinetics of fluoxetine: a review. Br J Psychiatry 1988; 153(suppl 3):47-50
18. Tollefson GD, Birkett M, Koran L, Genduso L: Continuation treatment of OCD: double-blind and open-label experience with fluoxetine. J Clin Psychiatry 1994; 55(Oct suppl):69-76
19. Wong DT, Fuller RW, Robertson DW: Fluoxetine and its two enantiomers as selective serotonin uptake inhibitors. Acta Pharm Nord 1990; 2:171-180
20. Wong DT, Bymaster FP, Reid LR, Mayle DA, Krushinski JH, Robertson DW: Norfluoxetine enantiomers as inhibitors of serotonin uptake in rat brain. Neuropsychopharmacology 1993; 8:337-344
21. Torok-Both GA, Baker GB, Coutts RT, McKenna KF, Aspeslet LJ: Simultaneous determination of fluoxetine and norfluoxetine enantiomers in biological samples by gas chromatography with electron-capture detection. J Chromatogr 1992; 579:99-106
22. Goodman WK, McDougle CJ, Price LH, Riddle MA, Pauls DL, Leckman JE: Beyond the serotonin hypothesis: a role for dopamine in some forms of obsessive-compulsive disorder? J Clin Psychiatry 1990; 51(Aug suppl):36-43
23. Renshaw PF, Guimaraes AR, Fava M, Rosenbaum JF, Pearlman JD, Flood JG, Puopolo PR, Clancy K, Gonzalez RG: Accumulation of fluoxetine and norfluoxetine in human brain during therapeutic administration. Am J Psychiatry 1992; 149:1592-1594
24. Karson CN, Newton JEO, Livingston R, Jolly JB, Cooper TR, Sprigg J, Komoroski RA: Human brain fluoxetine concentrations. J Neuropsychiatry Clin Neurosci 1993; 5:322-329
25. 1A receptor responsivity in obsessive-compulsive disorder: comparison of patients and controls. Arch Gen Psychiatry 1991; 48:540-547
26. Hollander E, DeCaria CM, Nitescu A, Gully R, Suckow RF, Cooper TB, Gorman JM, Klein DF, Liebowitz MR: Serotonergic function in obsessive-compulsive disorder: behavioral and neuroendocrine responses to oral m-chlorophenylpiperazine and fenfluramine in patients and healthy volunteers. Arch Gen Psychiatry 1992; 49:21-28